9-Me-BC vs Bromantane
Limited Research vs Moderate Research
synergistic Both compounds upregulate tyrosine hydroxylase through distinct pharmacological mechanisms (beta-carboline vs. adamantane pathways). Conceptually synergistic for dopaminergic restoration, though no formal studies have evaluated the combination. If combining, use conservative doses of each and monitor for signs of excessive dopaminergic stimulation.
Molecular Data
9-Me-BC Bromantane
Weight 182.22 Da 277.18 Da
Half-life Not well characterized in humans ~11 hours
Type Beta-carboline derivative (C12H10N2) Adamantane-bromophenyl derivative (C16H20BrN)
Key Benefits
9-Me-BC
01 Upregulates tyrosine hydroxylase expression, enhancing endogenous dopamine synthesis capacity
02 Promotes dopaminergic neuron differentiation and neurite outgrowth in preclinical models, suggesting genuine neurorestorative potential
03 Anti-inflammatory effects on microglia may protect dopaminergic neurons from neuroinflammatory damage
04 Potential application in restoring dopaminergic function after stimulant-induced downregulation or neurotoxic damage
05 Low effective dose (milligram range) compared to many other nootropic compounds
Bromantane
01 Upregulates endogenous dopamine synthesis via tyrosine hydroxylase gene expression, producing sustained motivational drive without depletion
02 Anxiolytic properties reduce stress and anxiety without sedation, creating a state of calm, focused energy
03 Actoprotective effects improve both physical and mental performance under stressful or fatiguing conditions
04 Very low abuse and dependence potential due to the absence of acute monoamine release or reuptake inhibition
05 Minimal tolerance development compared to traditional stimulants, supporting longer-term use patterns
06 Smooth onset and offset with no crash or rebound effects
Side Effects
9-Me-BC
Severe photosensitivity -- CRITICAL: skin becomes highly reactive to UV radiation during use, with risk of exaggerated sunburn, phototoxic skin reactions, and UV-induced DNA damage
Insomnia or sleep disruption (mitigated by morning-only dosing)
Mild headache during the first few days of use
Bromantane
Insomnia or difficulty falling asleep (if taken too late in the day)
Mild anxiety or restlessness at higher doses (above 100 mg)
Mild headache (uncommon, typically transient)
Contraindications
Inability to strictly avoid sun and UV exposure for the duration of use -- this is an absolute contraindication due to the risk of phototoxic DNA damage
Concurrent use of MAO inhibitors
Pregnancy and breastfeeding (no safety data available)
History of photosensitivity disorders or skin cancer
Concurrent use of other photosensitizing medications (tetracyclines, fluoroquinolones, thiazides, etc.)
Known hypersensitivity to bromantane or adamantane derivatives
Pregnancy and breastfeeding (insufficient safety data)
Severe hepatic impairment
Concurrent use of MAO inhibitors (theoretical risk of excessive dopaminergic activity)
Research Evidence
9-Me-BC Bromantane
Status Limited Research Moderate Research
References 5 studies 5 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.